医学
格尔德
加药
胃酸
消化性
消化性溃疡
重症监护医学
疾病
内科学
药理学
回流
分泌物
作者
Rajesh Upadhyay,Nilima Soni,Agam Vora,Amit Saraf,Deepak Haldipur,Dwaipayan Mukherjee,Dwijen Das,MANGESH HARIHAR TIWASKAR,Milind Nadkar,Naik Arun,Rajesh Kumar,Rakesh R. Bhadade,Ramesh R Rai,Samir Bhargava,Samir Parikh,Shiran Shetty,Surya Kant,Umesh Jalihal,V. G. Mohan Prasad,Ashwin Kotamkar
标识
DOI:10.59556/japi.73.0844
摘要
The suppression of gastric acid secretion has long been the cornerstone of treatment for acid peptic disorders (APDs). Proton pump inhibitors (PPIs) have played a central role in managing these conditions, but their effectiveness can be hindered by notable limitations such as refractoriness or treatment failure due to inadequate acid suppression in some gastroesophageal reflux disease (GERD) patients, nonadherence to prescribed regimens due to the complexity of dosing, variability of response, and nocturnal acid breakthrough, etc. Vonoprazan is a first-in-class potassium-competitive acid blocker (P-CAB), recently introduced in India and also approved in several countries such as Japan, South Korea, and the USA. Extensive clinical evidence suggests that vonoprazan offers more potent acid suppression than PPIs. This consensus from the Association of Physicians of India (API) has been developed with the objective of providing key recommendations for the appropriate clinical usage of vonoprazan across various subsets of APDs, thereby optimizing the existing therapeutic options and improving the care and management of APD patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI